AI assistant
Pharnext — Major Shareholding Notification 2017
Mar 29, 2017
1594_dva_2017-03-29_6a60be67-a638-43ed-b1b8-3ed6704bd8b4.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
Press release
Pharnext announces reclassification of its historical investor's shares, strengthening the position of core shareholders
PARIS, France, 5.45pm, 29 March, 2017 (CEST) – Pharnext SA (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, was informed of a reclassification of its historical investor's shares.
2,143,736 shares held by Truffle Capital, co-founder of Pharnext, and representing 19.9% ownership of the company, have just been reclassified to existing shareholders including two core shareholders: Pierre Bastid (+600,000 shares) and Claude Berda (+1,243,736 shares). Truffle Capital states that the funds selling the shares are mutual investment funds that have reached maturity and therefore had a regulatory obligation to exit from their investments and, that other recent funds invested in Pharnext's Initial Public Offering in July 2016.
The initial lock-up commitments relating to the shares have been assumed in full by their new owners.
After such reclassification, new ownership of Pharnext's shares and voting rights are as follows:
| Shares | % | Voting rights | % | |
|---|---|---|---|---|
| Founders and employees | 1,318,084 | 12.2% | 2,617,684 | 17.8% |
| Pierre Bastid (Zaka) | 2,542,301 | 23.6% | 3,267,901 | 22.3% |
| Claude Berda (CBLux) | 1,632,688 | 15.1% | 1,632,688 | 11.1% |
| Truffle Capital | 1,119,410 | 10.4% | 1,419,010 | 9.7% |
| Industrials (Galapagos, Ipsen, Mérieux, Dassault) | 694,021 | 6.4% | 856,621 | 5.8% |
| Public (institutionnals and individuals) | 3,486,111 | 32.3% | 4,891,511 | 33.3% |
| TOTAL | 10,792,615 | 14,685,415 |
PHARNEXT | THE NEXT MEDICINE
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics: Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several compositions of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, please visit www.pharnext.com
CONTACTS:
Pharnext Pierre Schwich Chief Financial Officer [email protected] +33 (0)1 41 09 22 30
Investor Relations (Europe)
MC Services AG Anne Hennecke [email protected] +49 211 529252 22
Media Relations (Europe) ALIZE RP Caroline Carmagnol Margaux Pronost [email protected] +33 (0)1 44 54 36 64
Investor Relations (U.S.)
Stern Investor Relations, Inc. Sarah McCabe [email protected] +1 212-362-1200
Media Relations (U.S.) Russo Partners Tony Russo, Ph.D. Victoria Meissner, M.D. [email protected] [email protected] +1 212-845-4251 +1 646-942-5627
Investor Relations (France) NewCap Julie Coulot [email protected] +33 (0)1 44 71 20 40